Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

A procalcitonin-guided algorithm does not reduce the length of intravenous antibiotic treatment significantly in children ...

An 11-year-old boy overcomes Guillain-Barré syndrome, a rare neurological disorder, with timely treatment, intensive care, ...

Data from the Minnesota Department of Health shows influenza levels remain significantly higher than the peaks recorded ...

Study findings indicated a transition from IV to enteral triazole therapy as a feasible option for pediatric patients with invasive candidiasis.

A groundbreaking UK study in The Lancet has examined whether an additional blood test called procalcitonin (PCT) could safely shorten the time children spend on intravenous (IV) antibiotics in ...

Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies ...

According to Celltrion, STEQEYMA is expected to be marketed in the United States beginning in February 2025. DISCLAIMER: Because of the generality of this update, the information provided herein may ...

The final, formatted version of the article will be published soon. Intravenous push (IVP) administration of anti-seizure medications is becoming increasingly popular among emergency departments. IVP ...

Opdivo was previously only available as a solution for intravenous (IV) infusion. The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study ...

This is a MedPage Today story. In late September, Hurricane Helene damaged a major supplier of intravenous (IV) fluids. In this report, we follow up on what has happened since. Hurricane Helene ...

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19).